XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaboration Agreements, License Agreement and Revenues - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail)
3 Months Ended
Mar. 31, 2024
USD ($)
Europe [Member] | Astellas Agreement [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Changes in revenue from changes to estimated variable consideration $ 0
Total Consideration 905,979,000
Europe [Member] | Astellas Agreement [Member] | License [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Total Consideration 618,975,000
U.S./RoW and China [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Changes in revenue from changes to estimated variable consideration 0
U.S./RoW and China [Member] | AstraZeneca Agreements [Member] | License [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Total Consideration 344,500,000
U.S./RoW and China [Member] | AstraZeneca Agreements [Member] | Co Development Information Sharing And Committee Services [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Total Consideration 625,600,000
U.S./RoW and China [Member] | AstraZeneca Agreements [Member] | China Performance Obligation [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Total Consideration 399,500,000
U.S./RoW and China [Member] | AstraZeneca Agreements [Member] | Product [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Cumulative Revenue $ 222,900,000